Clinical Trial Update: SPI-1005 Treatment in Moderate COVID-19 Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SPI-1005 in moderate COVID-19 patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection

Drugs mentioned

• SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Covid19, Corona Virus Infection | Phase 2 | Status: UNKNOWN